Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.51 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 7/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.41 |
| ▸ | SELP | P16109 | 1/20 | 0.40 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.39 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.37 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26468965 | 0.89 | FABP3 (0.56) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL2607968 | 0.86 | FABP3 (0.51) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL14947024 | 0.86 | FABP3 (0.51) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL12268499 | 0.84 | FABP3 (0.71) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL22982784 | 0.84 | FABP3 (0.71) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL488050 | 0.82 | FABP3 (0.76) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL19768669 | 0.82 | FABP3 (0.47) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL20319439 | 0.82 | FABP3 (0.47) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL30503997 | 0.81 | FABP3 (0.78) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL5959944 | 0.81 | FABP3 (0.51) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | FABP3 7/4885LPAR3 1320/4885LPAR1 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.